How to Help Your Patients Save Money on Griseofulvin: A Provider's Guide to Savings Programs

Griseofulvin is a generic medication, but "generic" doesn't always mean "affordable" at the pharmacy counter. Without insurance coverage or a discount program, patients may pay $80–$350 per month depending on the formulation. For a drug that may need to be taken continuously for 6–18 months (as in onychomycosis), that cost is a real barrier to completing treatment. Here's how you can help your patients reduce their out-of-pocket griseofulvin costs.

Understand the Cost Landscape

The retail cost of griseofulvin varies considerably by formulation:

Microsize 500 mg tablets (30-day supply): ~$223 retail; as low as $80 with GoodRx coupon

Ultramicrosize 250 mg tablets (60-tablet supply): ~$352 retail; as low as ~$101 with GoodRx coupon

Suspension 125 mg/5 mL (120 mL): From approximately $42 with discount programs

Patients on long-term therapy for onychomycosis may spend $500–$1,500 or more over the course of treatment without assistance. Patients prescribed griseofulvin for pediatric tinea capitis — who often come from underserved communities — are particularly vulnerable to cost-related prescription abandonment.

Strategy 1: Recommend Free Prescription Discount Cards

For uninsured or underinsured patients, prescription discount cards are the fastest and most accessible cost-reduction tool. Two free programs to recommend:

GoodRx: Reduces griseofulvin microsize by up to 64% off retail. Free to sign up; accepted at most major chains. Patients present the coupon (printout or phone app) instead of insurance.

SingleCare: A GoodRx competitor also offering free prescription savings. Prices vary by pharmacy, so it's worth checking both programs before the patient goes to the pharmacy.

Note: Discount cards cannot be combined with insurance. Instruct patients to present the coupon only if it's cheaper than their insurance copay. Staff can quickly check on GoodRx's website at the time of prescription entry.

Strategy 2: Verify and Optimize Insurance Coverage

Griseofulvin coverage varies by plan and formulation:

Microsize generic is typically Tier 1 or Tier 2 on most commercial plans ($0–$15 copay).

Ultramicrosize generic may be Tier 3 or Tier 4, particularly on Medicare Part D plans, resulting in higher copays of $30–$100+.

Medicaid and CHIP programs generally cover griseofulvin with minimal or no copay — confirm with state Medicaid formulary.

If a patient's plan places griseofulvin on a high tier, consider submitting a prior authorization (PA) request with clinical justification — particularly if griseofulvin is first-line for their indication (e.g., tinea capitis) and alternatives are less appropriate. Some plans will approve a lower cost-sharing tier with PA documentation.

Strategy 3: Prescribe the Microsize Formulation When Clinically Appropriate

For patients who can swallow tablets and have no specific indication for the ultramicrosize formulation, griseofulvin microsize 500 mg is generally less expensive at both retail price and insurance copay levels. If cost is a concern and both formulations are clinically acceptable, the microsize tablet is typically the more affordable option — and the one more likely to be found in stock.

Strategy 4: Write 90-Day Supplies for Long-Term Treatment

For onychomycosis patients on 6–18 months of griseofulvin therapy, prescribing a 90-day supply can reduce the per-unit cost, reduce the number of copays incurred, and improve adherence by limiting the number of trips to the pharmacy. Most commercial insurance and mail-order pharmacy programs incentivize 90-day fills. Note: the patient must confirm pharmacy stock before attempting to fill a 90-day supply of a specialty generic like griseofulvin.

Strategy 5: Guide Pediatric Patients to Medicaid and CHIP

Tinea capitis predominantly affects school-age children, and is more prevalent in lower-income and underserved communities. If a pediatric patient's family lacks insurance, help them understand their eligibility for Medicaid or CHIP. Staff can provide enrollment resources and assist families with the application process. Once enrolled, griseofulvin should be covered with minimal or no copay under virtually all state Medicaid plans.

Strategy 6: Compounding Pharmacy as a Last Resort for Affordability

Compounding pharmacies can sometimes offer griseofulvin suspension at competitive prices compared to commercially manufactured suspension, particularly in areas where commercial stock is unavailable and the only alternative is a special-order premium. However, compounded medications are typically not covered by insurance, so the patient pays out-of-pocket. This option works best when the commercial suspension is unavailable AND the patient cannot use tablets.

Note on Manufacturer Assistance Programs

There is no manufacturer-run patient assistance program (PAP) for griseofulvin, as it is an older, multi-source generic medication. Manufacturer PAPs are generally reserved for brand-name or specialty drugs. Discount card programs (GoodRx, SingleCare) and insurance coverage are the most reliable tools.

Helping Patients Find the Medication

Beyond cost, griseofulvin access is complicated by its inconsistent availability at retail pharmacies. Directing patients to medfinder's provider resources can help them locate griseofulvin in stock near them, without requiring multiple phone calls. This is particularly valuable for families of children with tinea capitis, where treatment delays can lead to worsening infection, kerion formation, and scarring.